R 1295

Drug Profile

R 1295

Alternative Names: R1295

Latest Information Update: 06 Nov 2006

Price : $50

At a glance

  • Originator Roche
  • Class Antiasthmatics
  • Mechanism of Action Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 30 Sep 2006 Phase-I clinical trials in Multiple sclerosis in Europe (unspecified route)
  • 31 Mar 2006 Discontinued - Phase-I for Multiple sclerosis in Europe (unspecified route)
  • 26 Apr 2005 Phase-I clinical trials in Multiple sclerosis in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top